Zenas BioPharma, Inc. Operating Expenses
Zenas BioPharma, Inc. (ZBIO) reported Operating Expenses of $108.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Zenas BioPharma, Inc. operating expenses for the quarter ending 2026-06-30 was $108.66M, a 96.98% increase year-over-year.
- Zenas BioPharma, Inc. operating expenses for the quarter ending 2026-03-31 was $77.35M, a 63.43% increase year-over-year.
- Zenas BioPharma, Inc. operating expenses for the quarter ending 2025-12-31 was $237.98M, a 292.56% increase year-over-year.
- Zenas BioPharma, Inc. operating expenses for the quarter ending 2025-09-30 was $52.58M, a 28.29% increase year-over-year.
- Zenas BioPharma, Inc. operating expenses for fiscal 2025 was $393.06M, a 132.73% increase from fiscal 2024.
- Zenas BioPharma, Inc. operating expenses for fiscal 2024 was $168.89M, a 93.80% increase from fiscal 2023.
- Zenas BioPharma, Inc. operating expenses for fiscal 2023 was $87.15M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.66M 10-Q · filed 2026-08-13 | $186.01M 10-Q · filed 2026-08-13 | $423.99M derived: sum of 3 quarters · filed 2026-08-13 | $476.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $77.35M 10-Q · filed 2026-05-13 | $315.33M derived: sum of 2 quarters · filed 2026-05-13 | $367.91M derived: sum of 3 quarters · filed 2026-05-13 | $423.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $237.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $290.56M derived: sum of 2 quarters · filed 2026-03-16 | $345.73M derived: sum of 3 quarters · filed 2026-08-13 | $393.06M 10-K · filed 2026-03-16 |
| 2025-09-30 | $52.58M 10-Q · filed 2025-11-12 | $107.74M derived: sum of 2 quarters · filed 2026-08-13 | $155.07M 10-Q · filed 2025-11-12 | $215.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $55.16M 10-Q · filed 2026-08-13 | $102.49M 10-Q · filed 2026-08-13 | $163.12M derived: sum of 3 quarters · filed 2026-08-13 | $204.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $47.33M 10-Q · filed 2026-05-13 | $107.95M derived: sum of 2 quarters · filed 2026-05-13 | $148.94M derived: sum of 3 quarters · filed 2026-05-13 | $188.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $60.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $101.61M derived: sum of 2 quarters · filed 2026-03-16 | $141.31M derived: sum of 3 quarters · filed 2026-03-16 | $168.89M 10-K · filed 2026-03-16 |
| 2024-09-30 | $40.98M 10-Q · filed 2025-11-12 | $80.69M derived: sum of 2 quarters · filed 2025-11-12 | $108.27M 10-Q · filed 2025-11-12 | $133.04M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $39.70M 10-Q · filed 2025-08-12 | $67.28M 10-Q · filed 2025-08-12 | $92.06M derived: sum of 3 quarters · filed 2025-08-12 | $106.44M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $27.58M 10-Q · filed 2025-05-15 | $52.36M derived: sum of 2 quarters · filed 2025-05-15 | $66.73M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $24.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $39.16M derived: sum of 2 quarters · filed 2025-03-11 | $87.15M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $14.38M 10-Q · filed 2024-11-12 | $62.37M 10-Q · filed 2024-11-12 |